Zymeworks (NASDAQ:ZYME) Earns "Sell (D-)" Rating from Weiss Ratings

Key Points

• Zymeworks' stock has been reaffirmed with a "sell (D-)" rating by Weiss Ratings, indicating concerns about its current performance.
• In contrast, Wall Street Zen upgraded the stock from a "hold" rating to a "buy" rating, reflecting differing opinions among analysts.
• Despite a recent quarterly earnings report showing a positive earnings per share of $0.03, Zymeworks has a negative net margin of 59.96% and continues to face challenges in profitability.

Zymeworks (NASDAQ:ZYME - Get Free Report)'s stock had its "sell (d-)" rating reaffirmed by equities research analysts at Weiss Ratings in a research report issued to clients and investors on Wednesday,Weiss Ratings reports.

Separately, Wall Street Zen raised Zymeworks from a "hold" rating to a "buy" rating in a report on Sunday, August 17th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock has an average rating of "Sell".

Zymeworks Stock Performance

ZYME traded up $0.25 on Wednesday, hitting $16.75. The company had a trading volume of 211,668 shares, compared to its average volume of 538,500. The stock has a market cap of $1.26 billion, a price-to-earnings ratio of -17.27 and a beta of 1.51. Zymeworks has a 1 year low of $9.03 and a 1 year high of $17.70. The stock's fifty day simple moving average is $14.88.

Zymeworks (NASDAQ:ZYME - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported $0.03 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.52) by $0.55. Zymeworks had a negative net margin of 59.96% and a negative return on equity of 21.59%. The company had revenue of $48.73 million for the quarter, compared to analyst estimates of $13.66 million.

Zymeworks Company Profile

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, and breast cancer; and ZW49, a biparatopic anti- human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.